Sector
PharmaceuticalsOpen
₹753Prev. Close
₹132.5Turnover(Lac.)
₹0.23Day's High
₹753Day's Low
₹742.552 Week's High
₹052 Week's Low
₹0Book Value
₹0Face Value
₹1Mkt Cap (₹ Cr.)
11,898.72P/E
38.28EPS
3.46Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 53.81 | 52.84 | 51.86 | 16.52 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,281.43 | 1,226.9 | 1,178.83 | 42.01 |
Net Worth | 1,335.24 | 1,279.74 | 1,230.69 | 58.53 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2019 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 659.56 | 703.47 | 624.01 | 541.56 |
yoy growth (%) | -6.24 | 12.73 | 15.22 | 16.67 |
Raw materials | -269.23 | -273.59 | -258.59 | -241.67 |
As % of sales | 40.82 | 38.89 | 41.44 | 44.62 |
Employee costs | -143.47 | -143.2 | -124.42 | -115.6 |
| Y/e 31 Mar( In .Cr) | Mar-2019 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | 40.89 | 58.55 | 10.68 | -80.33 |
Depreciation | -54.62 | -54.83 | -48.7 | -52.1 |
Tax paid | 7.4 | 1.15 | -4.56 | 16.33 |
Working capital | -64.6 | 1.14 | 120 | -2.06 |
Other operating items |
| Y/e 31 Mar | Mar-2019 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -6.24 | 12.73 | 15.22 | 16.67 |
Op profit growth | -30.73 | 47.93 | -845.2 | -86.64 |
EBIT growth | -25.21 | 118.5 | -192.55 | -58.99 |
Net profit growth | -375.33 | -910.65 | -97.07 | -47.41 |
| Particulars (Rupees in Crores.) | Mar-2011 | Mar-2010 | Mar-2009 | Mar-2008 | Mar-2007 |
|---|---|---|---|---|---|
Gross Sales | 530.78 | 490.26 | 318.41 | 278.25 | 326.73 |
Excise Duty | 13.36 | 11.02 | 11.14 | 9.42 | 13.65 |
Net Sales | 517.4 | 479.23 | 307.26 | 268.82 | 313.07 |
Other Operating Income | 8.98 | 9.27 | 4.98 | 13.77 | 0 |
Other Income | 3.74 | 14.43 | 17.2 | 125.36 | 12.73 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,709.35 | 130.19 | 4,10,142.32 | 1,181.05 | 0.79 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,482.85 | 70.31 | 1,45,762.16 | 594 | 0.55 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,415.25 | 24.56 | 1,14,322.24 | 1,438.15 | 0.92 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,286.5 | 60.94 | 1,11,165.87 | 485 | 0.85 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,451.2 | 52.28 | 1,01,098.24 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Rakesh Bhargava
Director
Rajiv Lochan Jain
Director
Michael Schonhofen
Director
Uday Chandrashekhar Shetty
Director
Maria Gobbi
Company Secretary
Nikhil Kulshreshtha
Whole-time Director
Nikhil Kulshreshtha
Director
Steffen Georg Roser
Director
Karsten Peter Lerch
Managing Director
Arvind Kumar Sharma
Chief Financial Officer
Sandeep Kumar Chotia
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Fresenius Kabi Oncology Ltd
Summary
Fresenius Kabi Oncology Ltd (formerly known as Dabur Pharma Ltd) is a leading Indian company for cancer research and anticancer products. The company develops, manufactures and markets speciality pharmaceutical products in the area of Oncology with manufacturing operations located in India & UK and marketing operations worldwide. The companys prime focus areas are New Chemical Entities (NCE), Noves Drug Delivery Systems (NDDS), discovery led filing of patents and development of Oncology generics.Fresenius Kabi (Singapore) Pte Ltd, a subsidiary of Fresenius SE, a body corporate incorporated in Germany, entered into an agreement with majority of shareholders of the company for acquisition of their stake. Consequent upon take over of shares, Fresinuis Kabl (Singapore) Pte Ltd now controls 90.89% stake in the company and the name of the company was changed from Dabur Pharma Ltd to Fresenius Kabi Oncology Ltd with effect from January 9, 2009.Fresenius Kabi Oncology Ltd was incorporated in the year 2003 as Dabur Pharma Ltd. The pharmaceutical business of Dabur India Ltd was demerged into a separate company with effect from April 1, 2003. The company is a market leader in the Oncology segment in India. Their plants are located at Baddi and Solan in Himachal Pradesh and Kalyani in West Bengal.During 2004-05, the company increased the installed capacity of Bulk Drugs by 14,387 Kg and with this the total installed capacity of Bulk Drugs increased to 54,491 Kg. For marketing their range
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
